Gabapentin Capsule
Product Images NDC 71335-1991

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1991). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Figure 06)

Mathematical formula representing creatinine clearance (CLCr), calculated using age, weight, serum creatinine, and a factor for female patients. The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for females.*

FDA Label Image

Structure Of Gaba (Gabapentin Figure 01)

Chemical structure diagram of gabapentin showing its molecular formula with functional groups including an amine and carboxylic acid attached to a cyclohexane ring.*

FDA Label Image

Figure-2 (Gabapentin Figure 02)

A line graph comparing mean pain scores over 8 weeks between placebo and gabapentin (3600 mg/day) groups. The x-axis represents weeks, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows the mean pain score ranging from 0 to 10. Gabapentin shows a decreasing trend in pain scores, while placebo remains relatively stable.*

FDA Label Image

Figure-3 (Gabapentin Figure 03)

Line graph showing mean pain score over 7 weeks comparing placebo with gabapentin at 1800 mg/day and 2400 mg/day doses. The X-axis shows time in weeks from baseline, and the Y-axis shows mean pain score. The graph is divided into a 3-week dose titration period and a 4-week fixed dose period, illustrating decreasing pain scores over time with gabapentin compared to placebo.*

FDA Label Image

Figure-4 (Gabapentin Figure 04)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' comparing placebo (PBO) and gabapentin (GBP) doses of 1800, 2400, and 3600 mg across two studies. The chart indicates statistically significant higher response rates for gabapentin doses versus placebo.*

FDA Label Image

Image (Gabapentin Figure 05)

A scatter plot showing the percentage difference on the y-axis and daily dose in mg on the x-axis for gabapentin. The plot includes data points from three studies labeled a, b, and c, with daily doses ranging from approximately 600 mg to 1800 mg and percentage differences between 5% and 20%.*

FDA Label Image

Label (Lbl713351991)

Label for Gabapentin 100 mg Capsules by Bryant Ranch Prepack, packaged in Burbank, CA. The label states the capsule is white and marked with 'CAPSULE 103.' It includes storage instructions to keep at 20-25°C (68-77°F), a warning that the drug may cause dizziness, and a safety notice to keep out of children's reach. The label also compares the product to Neurontin 100 mg capsules by Marksans Pharma Ltd and displays the NDC 71335-1991.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.